Mutant forms of ALK are implicated in a variety of cancers: activating point mutations of the native receptor drive the onset of a subset of neuroblastoma, as well as thyroid, and renal cancer, while oncogenic ALK gene translocations or inversions are found in non-small cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), inflammatory myofibroblastic tumor (IMT) and rare cases of other solid tumors [1]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.